David Sinclair on Lifespan, NMN, and the Future of Aging

Summary

A wide-ranging conversation covering Sinclair's career, the science behind Lifespan, and his predictions for longevity medicine. He discusses the TAME trial (metformin for aging), partial reprogramming, and why he believes the first person to live to 150 is already alive.

Key Takeaways

• 1

  The TAME trial is the first FDA-approved clinical trial targeting aging itself as a disease

• 2

  Partial reprogramming using Yamanaka factors (OSK subset) can reverse epigenetic age in mice without causing cancer

• 3

  Sinclair predicts biological age tests will be as routine as cholesterol checks within 10 years

• 4

  Intermittent fasting activates sirtuins and AMPK — the same pathways targeted by NMN and metformin

• 5

  The 'information theory' predicts that if we can restore the epigenetic program, we can restore youth

Molecules Discussed

Related Articles